Drugs / IMIFOPLATIN
IMIFOPLATIN
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03288480 | Dec 2017 → Sep 2020 | plasma cell myeloma | Promontory Therapeutics Inc. | Completed | No outcome recorded |
| Phase 1/24 trials | ||||||
| Phase 1/2 | NCT05357196 | Apr 2020 → Aug 2022 | biliary tract cancer | SciClone Pharmaceuticals | Unknown | No outcome recorded |
| Phase 1/2 | NCT03409458 | Apr 2018 → Jun 2022 | non-small cell lung carcinoma | Promontory Therapeutics Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT03439761 | Mar 2018 → May 2020 | cancer | SciClone Pharmaceuticals | Unknown | No outcome recorded |
| Phase 1/2 | NCT02884479 | Aug 2016 → Dec 2018 | non-small cell lung carcinoma | SciClone Pharmaceuticals International (Cayman) Development Limited | Unknown | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT05104736 | Apr 2022 → Dec 2027 expected | thymoma, thymus cancer | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 2 | NCT02266745 | Jul 2014 → Aug 2024 | castration-resistant prostate carcinoma | Promontory Therapeutics Inc. | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 18
| Date | Issuer | Release |
|---|---|---|
| 2025-12-22 | Promontory Therapeutics Inc. | Results Promontory Therapeutics Announces Interim Efficacy Requirement Reached on Phase 2 Study of PT-112 Monotherapy in Patients with Recurrent Thymoma promontorytx.com ↗
Of the first ten patients with thymoma assessed for tumor response in an ongoing phase 2 clinical trial at the NCI, three (30%) had experienced RECIST partial responses, an objective response rate that numerically exceeds that of the recent Phase 2 monotherapy data in the public domain with current off-label treatment options. |
| 2025-03-25 | Promontory Therapeutics Inc. | Results Promontory Therapeutics Announces Presentation on Clinical Immune Responses to PT-112 Monotherapy at the 2025 AACR Annual Meeting promontorytx.com ↗
including increases in activated T cells and NK cells, modulation of blood cytokines, and the emergence of novel T cell clones. |
| 2023-11-04 | Promontory Therapeutics Inc. | Results Promontory Therapeutics Presents Data on Molecular Mechanisms of PT-112's Immunogenic Effects promontorytx.com ↗
Data suggest that PT-112-induced ICD is mediated by endoplasmic reticulum (ER) and mitochondrial stresses, which are specific intra-cellular events that comprise part of the larger ICD mechanism. |
| 2023-10-14 | Promontory Therapeutics Inc. | Results Promontory Therapeutics Presents Data on the Molecular Effects of PT-112 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics promontorytx.com ↗
Our study shows that PT-112 inhibits ribosomal biogenesis in cancer cells. |
| 2023-10-05 | Promontory Therapeutics Inc. | Results Promontory Therapeutics Announces Early Phase 2 Clinical Trial Data From the National Cancer Institute, Demonstrating PT-112's Immune Activation in Thymic Epithelial Tumors promontorytx.com ↗
During an oral presentation at the International Thymic Malignancy Interest Group (ITMIG) 2023 Annual Meeting, Arun Rajan, MD, Principal Investigator at the NCI, highlighted PT-112's encouraging clinical activity, including evidence of immune activation. |
| 2023-06-02 | Promontory Therapeutics Inc. | Results Promontory Therapeutics Announces Preliminary Data from the National Cancer Institute Phase 2 Clinical Trial of PT-112 in Thymoma and Thymic Carcinoma at 2023 ASCO Annual Meeting promontorytx.com ↗
Based on preliminary data to date, PT-112 appears to be safe and tolerable, and clinically active in patients with recurrent TETs. |
| 2022-12-08 | Promontory Therapeutics Inc. | Results Promontory Therapeutics Presents Safety and Efficacy Data of PT-112 in Combination with PD-L1 Inhibition in Treatment of Advanced Non-Small Cell Lung Cancer at ESMO I-O 2022 promontorytx.com ↗
The poster titled, "A phase 2a study of the novel immunogenic cell death (ICD) inducer PT-112 plus avelumab in advanced non-small cell lung cancer patients," demonstrated that the PT-112 and avelumab combination is well-tolerated with manageable safety profile, and showed meaningful clinical benefits in patients without known predictive markers for immunotherapy response. |
| 2022-11-11 | Promontory Therapeutics Inc. | Results Promontory Therapeutics Presents on the Immunological Effects of PT-112 in Cancer Cell Mitochondria at SITC 2022 promontorytx.com ↗
The poster titled, "Immunologically relevant effects of PT-112 on cancer cell mitochondria" demonstrated that PT-112 caused anti-cancer activity, which is related to its ability to induce immunogenic cell death (ICD). |
| 2022-10-26 | Promontory Therapeutics Inc. | Results Promontory Therapeutics Reports PT-112's Effects on Human Prostate Cancer Cell Mitochondria at the 34th EORTC-NCI-AACR Symposium promontorytx.com ↗
Our findings show that PT-112 was broadly active across a variety of human prostate cancer cell lines and induced mitochondrial stress, |
| 2022-08-11 | Promontory Therapeutics Inc. | Results Promontory Therapeutics Announces Peer-Reviewed Publication in Cancers of Selective Effects of PT-112 in Cancer Cell Models Driven by Mitochondrial Dysfunction promontorytx.com ↗
Data showed PT-112 induces mitochondrial stress and immunogenic cell death (ICD) in tumor cells with mitochondrial deficiencies |
| 2022-06-16 | Promontory Therapeutics Inc. | Results Delimiting and delivering: Promontory co-founder 'can't hire fast enough' as small biotech expands vision promontorytx.com ↗
Published in the The Lancet's eclinicalMedicine journal, the data from 66 patients find PT-112 safe and well-tolerated in heavily pretreated cancer patients. |
| 2022-06-08 | Promontory Therapeutics Inc. | Results Promontory Therapeutics Announces Peer Reviewed Publication of First-in-Human Clinical Trial of PT-112 in The Lancet's eClinicalMedicine promontorytx.com ↗
Full data set shows PT-112 was safe and well-tolerated in heavily pre-treated cancer patients and elicited prolonged responses against thymoma and lung cancers, along with radiographic and serum marker improvement in prostate cancer |
| 2021-05-20 | Promontory Therapeutics Inc. | Results Phosplatin Therapeutics Reports Phase 1b Study Results of Immunogenic Cell Death Inducer PT-112 Plus PD-L1 Inhibitor avelumab in Metastatic Prostate Cancer at ASCO Annual Meeting promontorytx.com ↗
The combination was generally well tolerated and demonstrated meaningful anti-tumor effects. |
| 2020-12-07 | Promontory Therapeutics Inc. | Results Phosplatin Therapeutics Presents Phase I Dose Escalation Data of PT-112 in Patients with Relapsed / Refractory Multiple Myeloma at ASH Annual Meeting promontorytx.com ↗
Phosplatin Therapeutics LLC , a clinical stage pharmaceutical company focused on oncology therapeutics, presented new data showing monotherapy treatment with PT-112, the company's lead clinical agent, was feasible and well tolerated in heavily pre-treated, relapsed / refractory multiple myeloma patients. |
| 2020-10-27 | Promontory Therapeutics Inc. | Results Phosplatin Therapeutics Announces Data Revealing Novel Mechanistic Attributes for PT-112 at the 32nd EORTC-NCI-AACR Virtual Symposium promontorytx.com ↗ |
| 2020-09-18 | Promontory Therapeutics Inc. | Results Phosplatin Therapeutics Announces Results from Phase 1b Dose Escalation Study of PT-112 Plus Avelumab in Patients with Solid Tumors promontorytx.com ↗
The combination of PT-112 and avelumab was found to be safe and well tolerated in 36 heavily pre-treated solid tumor patients who have exhausted standard therapy options, the majority of whom had received prior immunotherapy. |
| 2020-02-18 | Promontory Therapeutics Inc. | Results Phosplatin Therapeutics Announces Publication in OncoImmunology promontorytx.com ↗
PT-112 causes the release of so-called damage associated molecular patterns (DAMPs), a signature of ICD, by dying cancer cells. |
| 2020-02-11 | Promontory Therapeutics Inc. | Results Phosplatin Therapeutics presents positive data from two phase I studies in metastatic castrate-resistant prostate cancer patients at the Genitourinary Cancers Symposium promontorytx.com ↗
Safety and biological activity demonstrated in heavily pre-treated mCRPC sub-population with PT-112 monotherapy and in combination therapy with anti-PD-L1 immune checkpoint inhibitor avelumab. |
All press releases naming this drug 32 releases
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IMIFOPLATIN | ChEMBL registry synonym — accepted as the source's own label CHEMBL4802248 ↗ |
| Known as | Phosplatin's Platinum | “PT-112 (Phosplatin's Platinum) Combine With Gemcitabine Injection for Advanced Solid Tumors” NCT05357196 ↗ |
| Known as | PT-112 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03409458 ↗ |
| Modality | Other / unclassified | “PT-112, a novel pyrophosphate-platinum immunogenic cell death inducer” PMID 35747193 ↗ May 2022 |
| Route | Intravenous | “PT-112 intravenously” PMID 35747193 ↗ May 2022 |